BIODESIX INC 8-K

What Happened

• Biodesix, Inc. announced its financial and operating results for the quarter ended March 31, 2026 in a press release dated May 4, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8-K filed the same day. The filing was signed by CFO Robin Harper Cowie.

Key Details

• Filing date: May 4, 2026 (Form 8-K, Item 2.02 and Item 9.01).
• Quarter covered: Q1 2026, ended March 31, 2026.
• Disclosure delivered via press release: Exhibit 99.1 is the press release announcing the quarterly financial and operating results.
• Form 8-K signed by Robin Harper Cowie, Chief Financial Officer.

Why It Matters

• This 8-K formally makes Biodesix’s Q1 2026 earnings and operating update public. Retail investors should review the referenced press release (Exhibit 99.1) for specifics on revenue, earnings (or loss), and any operational highlights or guidance updates.
• The filing is a routine but material disclosure of quarterly results; details in the press release could influence investor decisions about company valuation, outlook, and near-term trading.